Alfred Zippelius

26.1k total citations · 6 hit papers
281 papers, 13.3k citations indexed

About

Alfred Zippelius is a scholar working on Oncology, Immunology and Materials Chemistry. According to data from OpenAlex, Alfred Zippelius has authored 281 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Oncology, 91 papers in Immunology and 76 papers in Materials Chemistry. Recurrent topics in Alfred Zippelius's work include Material Dynamics and Properties (73 papers), Immunotherapy and Immune Responses (67 papers) and Cancer Immunotherapy and Biomarkers (66 papers). Alfred Zippelius is often cited by papers focused on Material Dynamics and Properties (73 papers), Immunotherapy and Immune Responses (67 papers) and Cancer Immunotherapy and Biomarkers (66 papers). Alfred Zippelius collaborates with scholars based in Switzerland, Germany and United States. Alfred Zippelius's co-authors include Haim Sompolinsky, Heinz Läubli, Pedro Romero, E. Gardner, Bernard Derrida, Mikäel J. Pittet, Petra Herzig, Eric D. Siggia, Daniel E. Speiser and Marcel P. Trefny and has published in prestigious journals such as Nature, Cell and Physical Review Letters.

In The Last Decade

Alfred Zippelius

274 papers receiving 13.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

2018 733 citations Daniela S. Thommen, Viktor H. Koelzer et al. Nature Medicine profile →
RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types

2019 502 citations Gianni Monaco, Alfred Zippelius et al. profile →
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

2020 477 citations Fabien Franco, Marcel P. Trefny et al. Nature Immunology profile →
Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion

2020 370 citations Yi-Ru Yu, Hana Imrichová et al. Nature Immunology profile →
Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy

2021 208 citations Ana Luísa Correia, Joao C. Guimaraes et al. Nature profile →
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

2021 195 citations Annegien Broeks, Petra Herzig et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alfred Zippelius Switzerland	58	5.2k	5.0k	2.8k	1.6k	1.6k	281	13.3k
Herbert Levine United States	84	4.2k 0.8×	3.2k 0.6×	7.5k 2.7×	3.1k 1.9×	3.5k 2.2×	461	24.0k
Denis Wirtz United States	80	2.3k 0.4×	943 0.2×	8.8k 3.1×	1.4k 0.9×	589 0.4×	258	22.5k
Qing Nie United States	51	2.0k 0.4×	2.4k 0.5×	7.8k 2.8×	280 0.2×	103 0.1×	288	14.5k
Eytan Domany Israel	68	1.9k 0.4×	716 0.1×	8.2k 2.9×	1.3k 0.8×	3.8k 2.4×	275	17.0k
Philip K. Maini United Kingdom	66	2.0k 0.4×	679 0.1×	6.3k 2.2×	252 0.2×	525 0.3×	396	16.2k
Stefan C. Müller Germany	67	1000 0.2×	541 0.1×	5.2k 1.8×	362 0.2×	835 0.5×	440	13.5k
Michael G. Rosenblum United States	62	1.6k 0.3×	2.0k 0.4×	3.6k 1.3×	255 0.2×	330 0.2×	279	21.6k
David E. Root United States	68	4.1k 0.8×	2.4k 0.5×	17.0k 6.0×	605 0.4×	664 0.4×	223	24.9k
Benjamin D. Simons United Kingdom	74	3.9k 0.7×	1.5k 0.3×	8.7k 3.1×	797 0.5×	1.9k 1.2×	241	20.4k
Hiroyuki Tomita Japan	40	1.8k 0.4×	874 0.2×	1.8k 0.7×	297 0.2×	490 0.3×	250	6.4k

Countries citing papers authored by Alfred Zippelius

Since Specialization

Citations

This map shows the geographic impact of Alfred Zippelius's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfred Zippelius with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfred Zippelius more than expected).

Fields of papers citing papers by Alfred Zippelius

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfred Zippelius. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfred Zippelius. The network helps show where Alfred Zippelius may publish in the future.

Co-authorship network of co-authors of Alfred Zippelius

This figure shows the co-authorship network connecting the top 25 collaborators of Alfred Zippelius. A scholar is included among the top collaborators of Alfred Zippelius based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfred Zippelius. Alfred Zippelius is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zingg, Andreas, Reto Ritschard, Helen Thut, et al.. (2025). Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors. Cancer Immunology Research. 13(7). 990–1003.

Herzig, Petra, Markus Germann, Petra Schwalie, et al.. (2025). PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer. Science Translational Medicine. 17(816). eadr3718–eadr3718. 1 indexed citations

Donninger, Howard, Xiang Zhang, Chi Li, et al.. (2023). Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy. Science Advances. 9(26). eadg3736–eadg3736. 42 indexed citations

Wang, Gaoyuan, Alfred Zippelius, & Marcus Müller. (2022). Phase Separation of Randomly Cross-Linked Diblock Copolymers. Macromolecules. 55(13). 5567–5580. 6 indexed citations

Hummelink, Karlijn, Vincent van der Noort, Mirte Muller, et al.. (2022). PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. Clinical Cancer Research. 28(22). 4893–4906. 26 indexed citations

Correia, Ana Luísa, Joao C. Guimaraes, Priska Auf der Maur, et al.. (2021). Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature. 594(7864). 566–571. 208 indexed citations breakdown →

Yu, Yi-Ru, Hana Imrichová, Haiping Wang, et al.. (2020). Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nature Immunology. 21(12). 1540–1551. 370 indexed citations breakdown →

Mantuano, Natália Rodrigues, Michal A. Stanczak, Isadora de Araújo Oliveira, et al.. (2020). Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation. Cancer Immunology Research. 8(10). 1262–1272. 50 indexed citations

Klar, Richard, et al.. (2019). A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression. Cancer Immunology Immunotherapy. 69(1). 57–67. 6 indexed citations

10.

Haas, Quentin, Kayluz Frias Boligan, Camilla Jandus, et al.. (2019). Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. Cancer Immunology Research. 7(5). 707–718. 110 indexed citations

11.

Thommen, Daniela S., Viktor H. Koelzer, Petra Herzig, et al.. (2018). A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nature Medicine. 24(7). 994–1004. 733 indexed citations breakdown →

12.

Thommen, Daniela S., Jens Schreiner, Philipp Müller, et al.. (2015). Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunology Research. 3(12). 1344–1355. 315 indexed citations

13.

Falcke, Martin, et al.. (2015). Mechanical properties of branched actin filaments. arXiv (Cornell University). 11 indexed citations

14.

Müller, Philipp, Matthias Kreuzaler, Tarik A. Khan, et al.. (2015). Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Science Translational Medicine. 7(315). 315ra188–315ra188. 269 indexed citations

15.

Zippelius, Alfred, Jens Schreiner, Petra Herzig, & Philipp Müller. (2015). Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment. Cancer Immunology Research. 3(3). 236–244. 112 indexed citations

16.

Müller, Philipp, Kea Martin, Sebastian Theurich, et al.. (2014). Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. Cancer Immunology Research. 2(8). 741–755. 150 indexed citations

17.

Wang, Ting, et al.. (2014). Active microrheology of driven granular particles. Physical Review E. 89(4). 42209–42209. 19 indexed citations

18.

Kranz, W. Till, Matthias Sperl, & Alfred Zippelius. (2010). Glass Transition for Driven Granular Fluids. Physical Review Letters. 104(22). 225701–225701. 52 indexed citations

19.

Broderix, Kurt, Henning Löwe, Peter Müller, & Alfred Zippelius. (1999). Shear viscosity of a crosslinked polymer melt. Europhysics Letters (EPL). 48(4). 421–427. 12 indexed citations

20.

Aspelmeier, Timo, et al.. (1997). Cooling dynamics of a dilute gas of inelastic rods. arXiv (Cornell University). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact